Are you saying IMU fudge the excellent clinical trial data which was why the FDA granted them Fast Track designation and ODD so quickly lol. IMU hasn't even completed Ph1 clinical trial for these 3 IP, there's still the 11c option which could fund some of the next clinical trial phase but it still won't be enough, they always needed to raise fund end of Ph1 clinical trial at a much higher pps.
Just like last time when the market didn't listen to what LC said about VAXINIA clinical trial, they are doing the same with LC and YF.
IMU Price at posting:
2.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)